| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Institute of Neurology (Drs. Freeman and Thompson), University College London; Institute of Health Sciences (Dr. Fitzpatrick), University of Oxford, United Kingdom; Department of Neurology (Dr. Hutchinson), St Vincent’s Hospital, Dublin, Ireland; Schering AG (Drs. Miltenburger and Dahlke, and K. Beckmann), Berlin, Germany; Department of Neurology (Dr. Kappos), University Hospital Basel, Switzerland; Department of Neurology (Dr. Polman), University Hospital Free University, Amsterdam, the Netherlands; and Universita "La Sapienza" di Roma (Dr. Pozzilli), Italy.
Address correspondence and reprint requests to Dr. A.J. Thompson, Department of Clinical Neurology, Queen Square, London WC1 N3BG, UK; e-mail: A.Thompson{at}ion.ucl.ac.uk
Background:— The recent randomized, controlled trial of interferon-ß1b (IFN-ß1b) in 718 patients with secondary progressive MS (SP-MS) demonstrated a significant effect on the development of disability as evaluated by the physician. Its effect on patient-reported health-related quality of life (HrQoL) is reported herein.
Methods:— In this multicenter, double-blind, randomized, placebo-controlled trial, outpatients with SP-MS scoring between 3.0 and 6.5 on the Expanded Disability Status Scale received either 8 x 106 IU of IFN-ß1b or placebo for up to 3 years. A range of outcomes was measured, including HrQoL, which was assessed using the Sickness Impact Profile (SIP), a self-report questionnaire validated for use in MS. Measurements were undertaken at baseline and at 6-monthly intervals thereafter for 36 months.
Results:— A slight positive effect on the HrQoL of the IFN group in comparison with the placebo group was found, which reached significance in the physical scale of the SIP at 6 and 12 months and at last visit. There was moderate correlation between physician-assessed evaluation of change and patient-reported change.
Conclusions:— IFN-ß1b may delay sustained deterioration in patient-reported HrQoL in SP-MS. Methods of interpreting change in HrQoL are currently insufficiently developed to determine how clinically important these changes are for this population.
This article has been cited by other articles:
|
|
 |
|
  A.G. Beiske, H. Naess, J.H. Aarseth, O. Andersen, I. Elovaara, M. Farkkila, H.J. Hansen, S.I. Mellgren, M. Sandberg-Wollheim, P.S. Sorensen, et al. Health-related quality of life in secondary progressive multiple sclerosis Multiple Sclerosis, April 1, 2007; 13(3): 386 - 392. [Abstract] [PDF]
|
|
|
|
|
|
D M Miller, J A Cohen, M Kooijmans, E Tsao, G Cutter, M Baier, and IMPACT Investigators Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study Multiple Sclerosis, April 1, 2006; 12(2): 180 - 186. [Abstract] [PDF]
|
|
|
|
 |
|
 A-K Isaksson, G Ahlstrom, and L-G Gunnarsson Quality of life and impairment in patients with multiple sclerosis J. Neurol. Neurosurg. Psychiatry, January 1, 2005; 76(1): 64 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D A Gruenewald, I J Higginson, B Vivat, P Edmonds, and R E Burman Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review Multiple Sclerosis, December 1, 2004; 10(6): 690 - 725. [Abstract] [PDF]
|
|
|
|
|
|
L. Kappos Effect of drugs in secondary disease progression in patients with multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(1_suppl): S46 - S55. [Abstract] [PDF]
|
|
|
|
 |
|
 S. J. Pittock, W. T. Mayr, R. L. McClelland, N. W. Jorgensen, S. D. Weigand, J. H. Noseworthy, and M. Rodriguez Quality of Life Is Favorable for Most Patients With Multiple Sclerosis: A Population-based Cohort Study Arch Neurol, May 1, 2004; 61(5): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kappos Effect of drugs in secondary disease progression in patients with multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S46 - S55. [Abstract] [PDF]
|
|
|
|
|
|
J M Morales-Gonzales, J Benito-Leon, J Rivera-Navarro, A J Mitchell, and GEDMA Study Group A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study Multiple Sclerosis, February 1, 2004; 10(1): 47 - 54. [Abstract] [PDF]
|
|
|
|
|
|
E L J Hoogervorst, M J Eikelenboom, B M J Uitdehaag, and C H Polman One year changes in disability in multiple sclerosis: neurological examination compared with patient self report J. Neurol. Neurosurg. Psychiatry, April 1, 2003; 74(4): 439 - 442. [Full Text] [PDF]
|
|
|
|
|
|
D. M Miller, R. A Rudick, M. Baier, G. Cutter, D. S Doughtery, B. Weinstock-Guttman, M. K Mass, E. Fisher, and N. Simonian Factors that predict Health-Related Q uality of Life in patients with relapsing -remitting multiple sclerosis Multiple Sclerosis, February 1, 2003; 9(1): 1 - 5. [Abstract] [PDF]
|
|
|
|
|
|
M W Nortvedt and T Riise The use of quality of life measures in multiple sclerosis research Multiple Sclerosis, February 1, 2003; 9(1): 63 - 72. [Abstract] [PDF]
|
|
|
|
|
|
D M Miller Health-related quality of life Multiple Sclerosis, August 1, 2002; 8(4): 269 - 270. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
